Skip to content
Clinical ResearchResearch compoundModerate evidence

KW‑6356

Experimental drug candidate for Parkinson's disease, tested in humans so far only in small studies.

NootropicDopaminergicDopaminergicNeuroprotectionDopamineAnti-fatigue
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassDopaminergic · Neuroprotection
Primary targetAdenosine A2A receptor antagonist / inverse agonist
Targets3 receptor targets
Half-lifeLong elimination half-life with an active metabolite (supports once-daily dosing)
OnsetOral; studied for daytime dosing in Parkinson's disease (exact peak timing depends on protocol)
EvidenceModerate evidence
Affected systemsDopamineAnti-fatigue

Contents

DETAILED OVERVIEW

What is KW-6356?

KW-6356 (sipagladenant) is an experimental drug candidate being developed to treat Parkinson's disease. It is not approved in most regions, cannot be sold as a dietary supplement and is not meant for self-medication; its use in humans currently takes place within clinical trials.

In the movement-control area of the brain, a substance called adenosine puts a brake on the action of dopamine; the compound blocks one of the receptors for adenosine, that is, it releases the brake. In animal models it improved movement and strengthened the effect of levodopa, causing few involuntary movements, and improvement was also reported in people with early Parkinson's disease, but only a few small studies have been done in humans so far. Constipation and inflammation of the nose and throat were among the most common complaints, and long-term safety in humans is only partly known. Its effect may add up with other adenosine blockers, such as caffeine. Safety in pregnancy and breastfeeding has not been established.

Mechanism

Adenosine A2A antagonist / inverse agonist

Evidence

Human Phase 2 (Parkinson's, investigational)

Legal status

Investigational, unapproved drug

Receptor profile

  • Adenosine A2A receptorsStrong
  • Striatal dopaminergic signaling (indirect)Moderate
  • Adenosine A1 receptors (high A2A selectivity)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Constipation, one of the most common complaints in early human trials
  • Nasopharyngitis, also frequently reported in early trials
  • Theoretical dyskinesia (involuntary movement) risk when combined with L-DOPA, though this appeared low in animal models
  • Headache and nausea, as is common with the adenosine antagonist class
  • Long-term safety in humans is only partly known: the compound is still investigational

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Unapproved investigational drug: appropriate only within a clinical trial protocol under medical supervision
  • Additive effect possible with other adenosine antagonists (e.g. caffeine, istradefylline)
  • Effects may be prolonged due to the active metabolite and long half-life: interaction profile in humans not fully characterized

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

KW-6356 (sipagladenant) is an experimental drug candidate still in development, being investigated for Parkinson's disease, with very little human data so far. In animal models and early-stage Parkinson's patients it improved motor function, and appears to boost the effect of L-DOPA without meaningfully raising the risk of unwanted movement side effects (dyskinesia). It has a long half-life, which in theory would allow once-daily dosing, but this is currently a research-stage compound, not an approved or marketed drug.

Telegram

Have a question about KW‑6356?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC20H19N3O4S
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.